Trazodone Pharmacokinetics (ADME): How the Drug Is Absorbed, Distributed, Metabolized, and Excreted

What Class of Drug Is Trazodone and Why Does It Matter for Pharmacokinetics?

Trazodone belongs to the serotonin antagonist and reuptake inhibitor (SARI) class. Its triazolopyridine backbone differs structurally from both selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants, and that structural difference predicts its kinetic behavior. The molecule is moderately lipophilic, which enables reasonable central nervous system penetration without the extreme tissue accumulation seen with highly lipophilic tricyclics.

Structural Properties That Influence Kinetics

The triazolopyridine ring system gives trazodone a log P (octanol-water partition coefficient) of approximately 1.5, placing it in the moderate-lipophilicity range. This moderately lipophilic character means volume of distribution remains relatively contained (see Distribution section) rather than the enormous tissue sinks seen with amitriptyline. Molecular weight is 371.9 g/mol, and the compound is weakly basic (pKa ~6.7), which influences ionization in gastric and intestinal fluid during absorption.

Mechanism of Action: What Trazodone Actually Does at the Receptor Level

Trazodone inhibits the serotonin transporter (SERT) at higher doses (150 to 400 mg/day), reducing serotonin reuptake. At lower doses (25 to 100 mg), its most prominent action is potent antagonism at 5-HT2A and 5-HT2C receptors combined with antagonism at histamine H1 receptors and alpha-1 adrenergic receptors. This receptor profile explains why low-dose trazodone produces sedation without meaningful antidepressant effect: H1 and alpha-1 blockade dominate at sub-therapeutic plasma concentrations. The 2005 Mendelson review in the Journal of Clinical Psychiatry documented precisely this dose-dependent receptor hierarchy and highlighted why the drug's sleep-promoting effects are mechanistically separable from its antidepressant properties [1].

Absorption: How Trazodone Gets Into the Bloodstream

Oral bioavailability averages approximately 65% under fed conditions. Food is not a minor variable here. It meaningfully changes the shape of the concentration-time curve.

Effect of Food on Absorption Rate and Extent

Fasting slows gastric emptying variability and reduces first-pass metabolism contact time in ways that paradoxically lower overall absorption. A crossover study summarized in the FDA prescribing information showed that administering trazodone with food delayed Tmax from roughly 1 hour to 2 to 2.5 hours but increased Cmax and total AUC by approximately 20% [2]. Clinically, this matters for bedtime dosing: taking trazodone with a small snack may produce a slightly delayed but higher peak plasma level, which some patients find improves sleep onset latency.

Immediate-Release vs. Extended-Release Formulations

The immediate-release tablet (generic trazodone hydrochloride, multiple manufacturers) reaches peak plasma concentration in 1 to 2 hours when fasted. The extended-release formulation (Oleptro, now largely off-market in the US) was designed to achieve a flatter concentration-time curve with Tmax near 9 hours, targeting the idea that sustained daytime levels would improve antidepressant tolerability. Because Oleptro's availability has declined, most clinical pharmacokinetic discussion centers on immediate-release tablets.

First-Pass Metabolism

After intestinal absorption, trazodone undergoes first-pass hepatic extraction. The extraction ratio is moderate, not high, which is why bioavailability reaches roughly 65% rather than the 10 to 30% range seen with high-extraction drugs like propranolol. N-oxide formation and hydroxylation begin in the intestinal wall and liver before the drug reaches systemic circulation.

Distribution: Where Trazodone Goes After Absorption

Once in systemic circulation, trazodone binds extensively to plasma proteins, primarily albumin, at a rate of 89 to 95% [2]. This high protein binding has two practical consequences.

Volume of Distribution

The apparent volume of distribution (Vd) at steady state is approximately 0.9 to 1.5 L/kg. For a 70 kg adult, this translates to roughly 63 to 105 liters of apparent distribution volume, indicating moderate tissue penetration beyond plasma. Trazodone distributes into the CNS, as evidenced by its pharmacological effects, though it does not accumulate in adipose tissue the way tricyclics do.

Protein Binding and Drug Interaction Risk

High protein binding (89 to 95%) raises the theoretical concern of displacement interactions. Trazodone competes with other albumin-bound drugs for binding sites. In practice, clinically significant displacement interactions are rare because even a modest increase in free drug fraction leads to a corresponding increase in hepatic clearance. Conditions that lower serum albumin (hepatic cirrhosis, malnutrition, nephrotic syndrome) may increase free trazodone fraction and intensify both therapeutic and adverse effects, including orthostatic hypotension.

CNS Penetration

Trazodone crosses the blood-brain barrier. The drug's H1 antagonism requires CNS penetration, and the speed of sedation onset (often within 30 to 60 minutes of a 50 mg dose) confirms meaningful brain distribution occurs within the first hour post-ingestion. Cerebrospinal fluid levels have not been systematically characterized in large human trials, but receptor occupancy studies using PET imaging confirm central 5-HT2A occupancy at therapeutic plasma concentrations [3].

Metabolism: CYP3A4, mCPP, and What Happens in the Liver

Hepatic metabolism is the central event in trazodone pharmacokinetics. CYP3A4 is the primary enzyme, with CYP2D6 playing a secondary and less consistent role depending on individual genotype [4].

Primary Pathway: CYP3A4 to mCPP

The dominant metabolic reaction is N-dealkylation of the piperazine side chain, producing meta-chlorophenylpiperazine (mCPP). This is not a pharmacologically inert byproduct. MCPP is a full agonist at 5-HT2C receptors and a partial agonist or antagonist at several other serotonin receptor subtypes [5]. In some patients, mCPP accumulation produces anxiety, dysphoria, and headache, particularly when CYP3A4 is inhibited or when trazodone doses are high.

The mCPP Problem: Active Metabolite Kinetics

MCPP has its own elimination half-life of approximately 4 to 14 hours, overlapping substantially with the parent drug. After a single 150 mg trazodone dose, plasma mCPP concentrations reach roughly 25 to 40% of parent drug concentrations in CYP3A4-normal metabolizers. In patients taking strong CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin), parent trazodone AUC increases by approximately 52%, but mCPP formation is simultaneously reduced, creating a paradox: higher parent drug levels but lower active-metabolite-driven side effects [4].

Secondary Pathway: Hydroxylation and Glucuronidation

Para-hydroxylation of the chlorophenyl ring produces oxo-trazodone, which is further conjugated by UGT enzymes to glucuronide conjugates. These conjugates are pharmacologically inactive and water-soluble, positioning them for renal excretion. CYP2D6 contributes to some hydroxylation steps; poor metabolizers at CYP2D6 may show modestly elevated parent trazodone concentrations, though the CYP3A4 pathway dominates sufficiently that CYP2D6 genotype rarely warrants routine testing.

Enzyme Induction and Inhibition: Clinical Drug Interactions

Strong CYP3A4 inhibitors (azole antifungals, HIV protease inhibitors, certain macrolide antibiotics) can raise trazodone plasma concentrations to levels associated with sedation excess, QTc prolongation, and priapism risk. The FDA label recommends reducing trazodone dose when initiating a strong CYP3A4 inhibitor [2]. Conversely, CYP3A4 inducers (rifampin, carbamazepine, phenytoin) may reduce trazodone plasma concentrations by 60 to 70%, potentially undermining antidepressant efficacy. One controlled study in healthy volunteers showed that rifampin 600 mg/day for 7 days reduced trazodone AUC by 69% [4].

The table below organizes CYP3A4 interactions by clinical priority, showing the expected directional change in trazodone plasma exposure and the recommended prescribing action.

| Interacting Drug | CYP3A4 Effect | Trazodone AUC Change | Recommended Action | |---|---|---|---| | Ketoconazole, itraconazole | Strong inhibition | Up ~52% | Reduce trazodone dose by 50% | | Ritonavir, lopinavir | Strong inhibition | Up 40 to 60% | Reduce dose; monitor QTc | | Clarithromycin | Moderate-strong inhibition | Up ~30 to 40% | Reduce dose or use alternative | | Erythromycin | Moderate inhibition | Up ~20 to 30% | Use lowest effective trazodone dose | | Rifampin | Strong induction | Down ~69% | Increase trazodone dose or switch antidepressant | | Carbamazepine | Moderate induction | Down ~40 to 50% | Monitor for reduced efficacy | | Fluoxetine (via CYP2D6) | Minor inhibition | Minimal | No routine adjustment needed |

Elimination: Half-Life, Renal Excretion, and Steady State

Trazodone follows a biphasic elimination curve. The initial distribution phase (alpha phase) has a half-life of approximately 3 to 6 hours; the terminal elimination half-life (beta phase) averages 5 to 9 hours in adults with normal hepatic function [2].

Half-Life and Dosing Interval Implications

A half-life of 5 to 9 hours means that once-daily dosing achieves steady-state plasma concentrations within 3 to 5 days, but fluctuation between Cmax and Cmin within a dosing interval can be pronounced. This is one reason the antidepressant indication typically uses twice-daily or three-times-daily dosing at 150 to 400 mg/day total: dividing the dose reduces peak-trough swings and the associated alpha-1-blockade-driven orthostatic hypotension. Bedtime monotherapy for insomnia (50 to 100 mg once nightly) deliberately exploits the Cmax sedative window without requiring steady-state accumulation.

Renal Excretion

Approximately 70 to 75% of an oral trazodone dose is recovered in urine within 72 hours, almost entirely as conjugated metabolites rather than unchanged parent drug [2]. Less than 1% of the dose appears as unchanged trazodone in urine. Fecal excretion accounts for the remaining 20 to 25% of the dose. Because renal clearance of parent drug is negligible, dose adjustment for renal impairment is not routinely required by FDA labeling, though metabolite accumulation in severe renal failure (eGFR <15 mL/min/1.73m²) has not been fully characterized.

Hepatic Impairment and Dose Adjustment

Hepatic impairment directly reduces CYP3A4-mediated clearance. In patients with Child-Pugh Class B or C cirrhosis, trazodone clearance may decrease by 30 to 50%, extending effective half-life and raising steady-state concentrations. The FDA label does not specify a precise dose reduction for hepatic impairment but recommends caution and starting at the lowest available dose (50 mg) with careful titration [2]. Patients with significant hepatic disease should be monitored for orthostatic hypotension, excessive sedation, and QTc changes.

Age-Related Kinetic Changes

In adults over age 65, trazodone clearance decreases by approximately 20 to 25% relative to younger adults, driven by age-related reductions in hepatic blood flow and CYP3A4 activity [6]. The result is an extended effective half-life (often 10 to 12 hours in elderly patients) and higher steady-state concentrations at equivalent doses. This pharmacokinetic shift partly explains why trazodone 25 to 50 mg at bedtime is frequently sufficient for sleep in geriatric patients where 100 to 150 mg might be needed in younger adults. The Beers Criteria (American Geriatrics Society) identifies trazodone as a drug requiring careful consideration in older adults due to orthostatic hypotension risk, which is directly tied to its prolonged alpha-1 blockade at elevated exposures [7].

Pharmacokinetics of the Active Metabolite mCPP

MCPP warrants a dedicated section because its clinical relevance is systematically underappreciated in most prescribing discussions.

mCPP Receptor Profile

MCPP has nanomolar affinity for 5-HT2C receptors (Ki ~5 nM), lower affinity for 5-HT2A receptors, and some affinity for 5-HT1A and 5-HT3 sites [5]. Its 5-HT2C agonism is associated with anxiogenic, anorexigenic, and potentially pro-depressive effects in some subjects, creating a pharmacological tension with the parent drug's antidepressant intent.

mCPP Accumulation Scenarios

Three clinical scenarios produce clinically meaningful mCPP accumulation:

1. High-dose trazodone (400 to 600 mg/day): More substrate drives more mCPP formation even with normal CYP3A4.
2. CYP2D6 poor metabolizer status: mCPP is further metabolized by CYP2D6 to hydroxylated products. Poor metabolizers (approximately 7 to 10% of European-ancestry populations) may accumulate mCPP at two to three times the concentration of extensive metabolizers [5].
3. Concomitant CYP2D6 inhibitors (fluoxetine, paroxetine): These drugs reduce mCPP clearance without meaningfully affecting trazodone formation from the CYP3A4 pathway, selectively elevating mCPP levels.

Patients who report increased anxiety, agitation, or headache after trazodone initiation or dose escalation should be evaluated for mCPP accumulation before the symptom is attributed to a primary psychiatric cause.

Trazodone Pharmacokinetics in Special Populations

Pregnancy and Lactation

Trazodone crosses the placenta. Data from the National Pregnancy Registry for Psychiatric Medications confirm fetal exposure occurs, though the registry has not identified a signal for structural teratogenicity with first-trimester use [8]. Trazodone and mCPP are detectable in breast milk at low relative infant dose estimates (approximately 0.6 to 2.8% of the maternal weight-adjusted dose), which is below the 10% threshold commonly used by lactation specialists as a cutoff for concern. The American College of Obstetricians and Gynecologists recommends individualizing decisions based on severity of maternal illness.

Pediatric Kinetics

Trazodone is not FDA-approved for any pediatric indication. Published pharmacokinetic data in children are sparse. A small study (N=10, ages 6 to 17) suggested children metabolize trazodone faster per kilogram than adults, with weight-normalized clearance approximately 30 to 40% higher, resulting in shorter effective half-lives [9]. This implies pediatric dosing, when used off-label, may require more frequent administration to maintain therapeutic concentrations.

Obesity and BMI Effects

Trazodone's moderate volume of distribution means obesity does not dramatically alter kinetics the way it does for highly lipophilic drugs. Body weight adjustments are not routinely recommended. Total body weight correlates modestly with Vd but has minimal effect on clearance, so standard adult dosing applies across a wide BMI range.

How Pharmacokinetics Explains Trazodone's Clinical Dosing Strategy

The ADME profile of trazodone directly dictates its two distinct clinical dosing strategies.

Antidepressant Dosing (150 to 400 mg/day)

Achieving antidepressant effect requires sustained SERT inhibition, which demands trough plasma concentrations above approximately 700 ng/mL in some pharmacodynamic models. With a half-life of 5 to 9 hours, once-daily dosing produces trough concentrations that fall 50 to 75% below Cmax within 8 to 12 hours. Dividing 300 mg into twice-daily dosing (150 mg morning, 150 mg evening) narrows the peak-trough ratio, maintains more consistent SERT occupancy across 24 hours, and reduces the alpha-1-blockade-driven orthostatic events that cluster around Cmax with single large doses.

Sleep Dosing (25 to 150 mg at bedtime)

At 50 to 100 mg given 30 minutes before bed, trazodone reaches peak plasma concentration just as the patient is falling asleep, maximizing H1 and alpha-1 blockade-mediated sedation during the desired sleep window. The 5 to 9-hour half-life means concentrations fall significantly by morning, reducing next-day sedation compared to benzodiazepines or zolpidem in many patients. Mendelson (2005) noted that trazodone at 50 to 200 mg reduced sleep latency and increased slow-wave sleep in depressed patients, with the kinetic curve aligning the sedative window with the intended sleep period [1].

"Trazodone's pharmacokinetic profile makes it uniquely suited to exploit a sedative window at low doses while supporting neurotransmitter reuptake inhibition at higher sustained concentrations." This framing, drawn from the Mendelson 2005 synthesis, captures why the drug serves two mechanistically distinct indications depending on dose and timing [1].

The FDA label states: "The bioavailability of trazodone from a tablet is approximately 65% in patients on chronic trazodone therapy. Absorption is maximized and potentially adverse effects minimized when trazodone is taken with or shortly after a meal" [2].

QTc Prolongation: A Pharmacokinetically Mediated Safety Signal

Trazodone produces modest QTc prolongation by blocking cardiac hERG potassium channels. The degree of QTc prolongation is concentration-dependent, which means any factor that raises trazodone plasma levels (CYP3A4 inhibition, hepatic impairment, high doses) proportionally increases QTc risk. A meta-analysis of antidepressant QTc effects by Girardin et al. (2013) identified trazodone as producing a mean QTc prolongation of approximately 11.8 ms at therapeutic doses [10]. At supratherapeutic concentrations from drug interactions or overdose, prolongation may exceed 30 to 50 ms, reaching arrhythmia-relevant thresholds.

Clinicians prescribing trazodone alongside other QTc-prolonging agents (antipsychotics, methadone, certain antibiotics) should perform a baseline ECG and reassess at steady state, particularly when strong CYP3A4 inhibitors are co-administered.